The Hidden Code: How RNA Sequencing Is Rewriting China’s Mitochondrial Disease Diagnostics

Chinese scientists have made a significant leap in diagnosing mitochondrial diseases, a group of inherited metabolic disorders that have long baffled clinicians due to their extreme genetic and clinical variability. In a study published in Annals of Clinical and Translational Neurology, researchers from China applied RNA sequencing (RNA-seq) to skin fibroblasts from 140 pediatric patients who had previously been left undiagnosed after whole exome sequencing (WES). The results were striking: an additional 25% of these patients finally received a genetic diagnosis.

The power of this approach lies in its ability to detect what DNA sequencing alone misses. The team uncovered cryptic splicing events, synonymous mutations, deep intronic variants, and even a recurrent East Asian founder mutation in the ECHS1 gene that had been entirely overlooked. Notably, the study found that 14% of protein-truncating variants predicted to be destroyed by nonsense-mediated decay (NMD) actually escaped degradation, revealing a hidden layer of functional genetic complexity. By integrating RNA-seq with whole genome sequencing (WGS) in six cases where RNA flagged an anomaly but WES found nothing, the researchers closed diagnostic gaps that had persisted for years.

Why it matters:
This advancement transforms the diagnostic odyssey for thousands of families in China. For healthcare systems grappling with the high burden of undiagnosed neurometabolic disease, the integration of transcriptomics into routine genomic testing offers a practical, cost-effective path to precision medicine. It signals a shift in how China approaches rare disease diagnosis, proving that the missing answer is often not in the DNA code itself, but in how that code is read.

Source →